Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2935 - Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Takeshi Nagasaka

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Nagasaka1, A. Nyuya1, H. Tanioka1, Y. Katata1, M. Yokota2, F. Taniguchi3, T. Kawai4, Y. Mori4, K. Shigeyasu4, M. Okawaki1, M. Yamamura1, Y. Umeda4, A. Tsuruta5, T. Ueno5, Y. Yamaguchi1

Author affiliations

  • 1 Medical Oncology, Kawasaki Medical School Hospital, 701-0192 - Kurashiki/JP
  • 2 General Surgery, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 3 Surgery, Iwakuni Clinical Hospital, 740-8510 - Iwakuni/JP
  • 4 Gastroenterological Surgery, Okayama University Hospital, 700-8558 - Okayama/JP
  • 5 Digestive Surgery, Kawasaki Medical School Hospital, 701-0192 - Kurashiki/JP
More

Resources

Abstract 2935

Background

POLE proofreading mutations cause ultrahypermutant-phenotype in colorectal cancer (CRC) but the characters of POLE mutations are still obscure in contrast to Lynch syndrome or sporadic microsatellite instability (MSI). Herein, we examined mutation profiles of POLE in 1,039 CRC Japanese patients, and tried to clarify clinico-pathological features of hypermutant CRC patients with respect to POLE mutations, Lynch syndrome and sporadic MSI.

Methods

We analyzed POLE pathogenic hotspot (exon9, 13 and 14), BRAF codon 600 and KRAS exon 2 mutations by Sanger sequencing. MSI status was confirmed by a multiplex PCR assay. MSI positive cases were confirmed the four mismatch repair (MMR) proteins (MLH1, MSH2, PMS2, and MSH6) expression. Germline mutations were analyzed by Sanger sequencing and a TruSight One Sequencing Panel using a next generation sequencer.

Results

Of 1,039 CRC patients, only four cases showed POLE pathogenic mutations (two P286R, one V411L and one S459F). The four POLE-mutant CRCs showed no MSI. CRC with MMR deficient (=MSI) were observed in 58 cases (5.6%). Of CRCs with MSI, Lynch syndrome was found in 17 cases and the rest of 41 cases were sporadic MSI. Therefore, we divided 1,039 CRCs into the four subsets; POLE-mutant (POLE; n = 4, 0.4%), Lynch syndrome (LS; n = 17, 1.6%), sporadic MSI (MSI; n = 41, 4.0%), and non-hypermutant CRCs (NH; n = 997, 94.0%). Mean age at diagnosis in POLE/LS/MSI/NH was 52.5/55.7/73.6/65.9 years, respectively (P< .0001). Frequency of female in POLE/LS/MSI/NH was 50/23.5/61/41% (P = 0.03). The primary tumor located at the right colon was observed in 100/35/80.5/30% of POLE/LS/MSI/NH (P< .0001). BRAF mutation was observed in 49% of MSI and 4% of NH while KRAS mutation was in 35% of LS and 32% of NH (P< .0001). Interestingly, 100/82/78% of POLE/LS/MSI tumors were diagnosed at the earlier stage, I or II, while 46% of NH (P< .0001). The recurrence free survival rate at 5-years was better in POLE (100%)/LS (86%)/MSI (94%) compared with that in NH (74%).

Conclusions

POLE-mutant CRC was rare, observed in the younger without family history, located at the right colon, and diagnosed at the earlier stage.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

The Ministry of Education, Culture, Sports, Science and Technology (MEXT).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.